Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Switzerland

Dueckelmann, A. M.; Fink, Daniel; Harter, Philipp; Heinzelmann, Viola; Marth, Christian; Mueller, Mark; Reinthaller, Alexander; Tamussino, Karl; Wimberger, Pauline; Sehouli, Jalid

doi:10.1007/s00404-018-4715-7

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the definite role of this novel therapy as an alternative to the existing treatment options has still to be established. It remains an experimental treatment modality and should not be performed outside the framework of prospective, controlled studies, as stressed by the AGO [108]. The results of ongoing randomized trials comparing systemic chemotherapy with PI-PAC in platinum-resistant recurrent ovarian cancer are eagerly awaited [109,110].…”

Section: Pressurized Intraperitoneal Aerosol Chemotherapymentioning

confidence: 99%

Pharmacological considerations regarding intraoperative hyperthermic intraperitoneal chemotherapy for ovarian cancer

2021

EJGO

View full text Add to dashboard Cite

Since ovarian cancer is limited to the peritoneal cavity for a prolonged period during the disease course, intraperitoneal chemotherapy seems a rational treatment option for residual peritoneal disease after cytoreductive surgery. Intraperitoneal when compared with intravenous chemotherapy exhibits a clear pharmacokinetic benefit. Performing intraperitoneal chemotherapy under hyperthermic conditions, as in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC), may enhance its therapeutic efficacy. Herein, the pharmacological aspects of (hyperthermic) intraperitoneal chemotherapy are discussed, including pharmacokinetics, drug penetration depth into the tumour, drug characteristics, optimal drug choice and the role of hyperthermia. Further clinical pharmacological studies are needed to appraise the optimal drug regimen for HIPEC in patients with primary and recurrent ovarian cancer. Development of new drugs and drug formulations may further improve the efficacy of HIPEC in the future.

show abstract

Section: Pressurized Intraperitoneal Aerosol Chemotherapymentioning

confidence: 99%

Pharmacological considerations regarding intraoperative hyperthermic intraperitoneal chemotherapy for ovarian cancer

2021

EJGO

View full text Add to dashboard Cite

show abstract

Cited by 1 publication

References 0 publications

Pharmacological considerations regarding intraoperative hyperthermic intraperitoneal chemotherapy for ovarian cancer

Pharmacological considerations regarding intraoperative hyperthermic intraperitoneal chemotherapy for ovarian cancer

Contact Info

Product

Resources

About